SALT LAKE CITY, July 26, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its
fiscal fourth-quarter 2016 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, August 9,
2016. During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, CFO, will provide an overview of Myriad’s
financial performance for the fiscal fourth-quarter and provide a business update.
To listen to the call, interested parties in the United States may dial 800-698-1231 or +1 303-223-4380 for international
callers. All callers will be asked to reference reservation number 21814778. The conference call also will be available
through a live webcast and a slide presentation pertaining to the earnings call will also be available under the investor section
of our website at www.myriad.com. A replay of the call will be available two hours after the end of the call
for seven days and may be accessed by dialing 800-633-8284 within the United States or +1 402-977-9140 for international callers
and entering reservation number 21814778.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that:
determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment
decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower
healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer
testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue
contribution from international markets. For more information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary
Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and Prolaris are trademarks or registered
trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F,
MYGN-G.
Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.com